Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays

Description

The primary objective is to assess the ability of COVID-19 IgG and IgM assays to detect an immune response in COVID-19 patients in the Henry Ford Health System (HFHS), both during hospitalization and over the following 12 months.

Conditions

Covid19

Talk to us

Study Overview

On this page

Study Details

Study overview

The primary objective is to assess the ability of COVID-19 IgG and IgM assays to detect an immune response in COVID-19 patients in the Henry Ford Health System (HFHS), both during hospitalization and over the following 12 months.

Initial and Sustained Immunity to SARS-CoV-2 Measured by Serologic Assays on an Automated Immunoassay System

Sustained Immunity to COVID-19 as Measured by SARS-CoV-2 Serology Assays

Condition
Covid19
Intervention / Treatment

-

Contacts and Locations

Detroit

Henry Ford Health System, Detroit, Michigan, United States, 48202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients ≥18 years of age
  • * Positive COVID-19 by RT-PCR SARS-CoV-2 assay
  • * Patients must have a serum sample stored by pathology or within the TCRC biorepository around the date of their COVID-19 RT-PCR positive test
  • * \< 18 years of age
  • * negative for RT-PCR
  • * no serum sample

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Henry Ford Health System,

Study Record Dates

2024-06